EPFL

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Retrieved on: 
Monday, April 1, 2024
Novartis, Cardiovascular disease, Science, EPFL, Risk, Patient, NAMS, Harvard Business School, CBO, Partner, McKinsey & Company

“We are privileged to welcome Juliette to our management team as CBO,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.

Key Points: 
  • “We are privileged to welcome Juliette to our management team as CBO,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
  • Prior to joining Forbion, Ms. Audet was a principal at the Novartis Venture Fund based in Cambridge, MA.
  • She also worked at Novartis AG for their commercial division and at McKinsey and Company focusing on Pharma and Biotech.
  • She earned her M.B.A. with distinction from Harvard Business School and her M.Sc.

Dr. Reymond Clavel and Marc-Olivier Demaurex, Pioneers of the Delta Robot, and Robotics Leader Joe Gemma Selected for 2024 Joseph F. Engelberger Robotics Awards

Retrieved on: 
Thursday, April 4, 2024
Technology, Mobile, Wireless, Packaging, Engineering, Robotics, Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Transport, Hardware, Other Manufacturing, Logistics, Supply Chain Management, Textiles, Joseph, University, Hermes, Artificial intelligence, Automation, Original equipment manufacturer, KUKA, Education, RIA, Corner, Organization, Research, Gemma, Robotic Industries Association, Family, Conference, Growth, EPFL, Wauseon, Ohio, Doctor of Philosophy, Plaque, École polytechnique, Japan Robot Association

The Association for Advancing Automation (A3) announced three longtime industry pioneers as the winners of the 2024 Joseph F. Engelberger Robotics Awards, the world's most prestigious robotics honor.

Key Points: 
  • The Association for Advancing Automation (A3) announced three longtime industry pioneers as the winners of the 2024 Joseph F. Engelberger Robotics Awards, the world's most prestigious robotics honor.
  • Marc-Olivier Demaurex, was selected as a technology winner for his role in pioneering the Delta robot and bringing it to market.
  • The Joseph F. Engelberger Robotics Awards are named after the late Joseph F. Engelberger, known throughout the world as the founding force behind industrial robotics.
  • “The honorees of this year’s Joseph F. Engelberger Robotics Awards have all played critical roles in the development and growth of our industry,” said Jeff Burnstein, president of A3.

Archer and EPFL Co-Develop a Single Chip Integrated Pulsed Electron Spin Resonance Microsystem

Retrieved on: 
Monday, March 25, 2024
Semiconductor, Hardware, Health, Technology, Health Technology, BiCMOS, CMOS, EPFL, HEMT, Research, ASX, IHP, Silicon–germanium, AXE, ESR, Electronics

Archer Materials Limited (“Archer”, the “Company”, “ ASX: AXE ”), a semiconductor company advancing the quantum technology and medical diagnostics industries, has built a single chip integrated pulsed electron spin resonance (“p-ESR”) microsystem, with its research partner École Polytechnique Fédérale de Lausanne (“EPFL”) in Switzerland.

Key Points: 
  • Archer Materials Limited (“Archer”, the “Company”, “ ASX: AXE ”), a semiconductor company advancing the quantum technology and medical diagnostics industries, has built a single chip integrated pulsed electron spin resonance (“p-ESR”) microsystem, with its research partner École Polytechnique Fédérale de Lausanne (“EPFL”) in Switzerland.
  • Archer and EPFL intend to use the p-ESR microsystem to perform complex measurements involving the potential electron spin manipulation of Archer’s 12CQ quantum materials.
  • The miniaturisation and electron spin sensitivity of the p-ESR microsystem also allows Archer to explore opportunities in developing quantum sensors, advanced spectrometers, and analytical devices.
  • Commenting on the development of the p-ESR chip, Dr Mohammad Choucair, CEO of Archer, said,
    “The engineering of a new pulsed ESR chip is a noteworthy achievement by the teams at Archer and EPFL.

COMMUNICATIONS OF THE ACM RELAUNCHED AS OPEN ACCESS, WEB-FIRST PUBLICATION

Retrieved on: 
Tuesday, March 12, 2024
Association for Computing Machinery, Information technology, Science, EPFL, Communications of the ACM, Research, News, Communication, University, Volunteering, CACM, Student, ACM, Multimedia, Engineering, Publishing

NEW YORK, March 12, 2024 /PRNewswire/ -- ACM, the Association for Computing Machinery, has relaunched Communications of the ACM (CACM), the organization's flagship magazine, as a web-first publication, accessible to everyone without charge. First published in 1958, CACM is one of the most respected information technology magazines. Providing news, expert commentary, and peer-reviewed research, CACM straddles the lines between a popular science magazine, a technical resource for industry professionals, and a scientific journal. CACM regularly receives very high "impact factors"—a metric used in academic publishing to gauge a publication's influence within its designated field.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- ACM, the Association for Computing Machinery, has relaunched Communications of the ACM (CACM), the organization's flagship magazine, as a web-first publication, accessible to everyone without charge.
  • In relaunching Communications of the ACM as an open access publication, all legacy and future CACM articles will be freely available to and accessible by everyone on the CACM website and in the ACM Digital Library.
  • The community's continued support of ACM through membership and the ACM Open model is essential to keeping ACM and CACM strong.
  • Even as we change the publication model, the foundation of CACM remains strong as ACM has sufficient resources to support a high-quality editorial process.

Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Nature Chemical Biology, General partnership, Drug development, Growth, Drug discovery, Macrocycle, Swiss, Seed, EPFL, Patient, Medicine, Nature Communications, CBO, Pharmaceutical industry

The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’.

Key Points: 
  • The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’.
  • nCycles are systematically designed by Orbis’ nGen1 platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
  • It’s a milestone for drug development,” said Morten Døssing, Chair of the Orbis Board and Partner at Novo Holdings.
  • Additionally, research recently published in Nature Chemical Biology demonstrates nGen’s ability to deliver nCycles that are orally bioavailable, marking a new era for macrocycle drug discovery.

EH Group Joins H2MARINE Project to Develop Next Generation Maritime Fuel Cells

Retrieved on: 
Thursday, February 29, 2024
Environmental Issues, Alternative Energy, Energy, Technology, Environment, Green Technology, Engineering, Maritime, Transport, Other Technology, Climate Change, Manufacturing, Hydrogen, EH, ZSW, Multimedia, DANA, FC, FCS, Entrepreneurship, Beyond Gravity, University, EPFL, VTT, University of Freiburg, ThyssenKrupp Marine Systems, PEM, Pressure, Renewable energy

EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).

Key Points: 
  • EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).
  • The project is committed to innovation in hydrogen technologies, focused on the development of next generation PEM fuel cell stacks for marine applications.
  • Based on its unique FC technology, EH Group will contribute its high power density stacks, further developed and optimised for marine use.
  • “Our high power density fuel cell technology has been recognised in its use for maritime applications, and we are delighted to contribute to its further development in this project.

Spiden Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding

Retrieved on: 
Saturday, January 6, 2024
Clarke Error Grid, Ismene, EPFL, ETH Zurich, Data analysis, Health, Apple, MARD, AI, Machine learning, Miniaturization, Biomarker, Longevity, Calibration, Head

Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.

Key Points: 
  • Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.
  • Spiden has achieved remarkable scientific progress in non-invasive glucose sensing.
  • This achievement is the latest important step towards a calibration-free and miniaturized device for non-invasive glucose monitoring.
  • A larger funding round is planned for H2 in 2024, which will provide Spiden with sufficient capital to bring its product to market and become profitable.

Global Steerable Needles (Bevel-tip Flexible, Symmetric-tip) Market Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Medical Devices, Health, Cleveland Clinic, EPFL, NCBI, Biopsy, Government, Brushed DC electric motor, Needle, Hospital, Cancer, DSM-IV codes, USD, Molecular Modeling Database, Growth, ARC, RAS, Cardiovascular disease, Medical device

The "Steerable Needles Market Size, Share & Trends Analysis Report By Type (Bevel-tip Flexible, Symmetric-tip), By Application (Biopsy, Tumor Ablation, Robotic Assisted Surgery), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Steerable Needles Market Size, Share & Trends Analysis Report By Type (Bevel-tip Flexible, Symmetric-tip), By Application (Biopsy, Tumor Ablation, Robotic Assisted Surgery), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Thus, an increasing number of robotic-assisted surgery (RAS) cases are anticipated to boost demand for steerable needles during the forecast period.
  • These advancements have led to the development of more precise and accurate steerable needles and steerable needles that are compatible with a wide range of imaging modalities.
  • This initiative will strengthen the adoption of newly launched steerable needles worldwide, thereby driving the market growth.

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Retrieved on: 
Friday, December 1, 2023
AC, Medicine, EPFL, Boehringer Ingelheim, CFO, Acquisition, Vaccine, Doctor of Philosophy, Therapy, Interim management, Interim, CSO, EUR, Lancaster University, Swiss

Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.

Key Points: 
  • Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.
  • Dr. Madiha Derouazi, an accomplished immunologist, joins from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines.
  • Christopher Roberts joined AC Immune in 2019 and has served as Vice President, Finance and Interim CFO of AC Immune since 2022.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am delighted to welcome Madiha Derouazi as our new CSO and to confirm Chris as CFO.

Swiss Startup Aesyra Raised $3 Million in Seed Financing from Global Investors to Advance Innovations to Tackle Bruxism and Sleep Apnea

Retrieved on: 
Wednesday, December 13, 2023
Health Technology, Manufacturing, Other Health, Finance, Business, General Health, Professional Services, Biometrics, Medical Devices, Neurology, Fitness & Nutrition, Dental, Other Manufacturing, Biotechnology, Data Analytics, Health, Sleep, Basler Kantonalbank, Bruxism, Sleep disorder, Sleep apnea, Patient, Algorithm, Growth, EPFL, AI, Quality of life, Pharmaceutical industry

Aesyra , a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing.

Key Points: 
  • Aesyra , a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing.
  • The new financing will support the development and commercialization of Aesyra’s AesyBite® line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea.
  • Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide.
  • "This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra.